News

20/02/2012

Oryzon participates in a R&D European consortium in Parkinson’s disease

06/02/2012

Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease

26/01/2012

Oryzon to Present at 4th CHI X-Gen Congress, Epigenetics, Targets and Therapies on March 6

15/09/2011

Oryzon will launch its first product onto the market

The clinical trial performed in 16 Spanish hospitals shows that its reliability when it comes to ruling out the presence of tumour is 97%.

07/07/2011

Oryzon on the official program of the Euromediag International Convention (EIC 2011)

06/07/2011

Dr. Marta Palicio, Scientific Business Developer at Oryzon, has been invited to participate in the roundtable Biomarkers and translational medicine: new paradigms for personalized medicine

27/06/2011

Oryzon is present at the Bio International Convention of USA

08/06/2011

Oryzon is present in the 76th Spanish National Congress of Urology

17/05/2011

Oryzon presents the results of the clinical study of GynEC-Dx: detection of endometrial cancer product

01/04/2011

Oryzon to Present at BioTrinity 2011 Conference in UK